SAR 425899

Drug Profile

SAR 425899

Alternative Names: SAR-425899

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sanofi
  • Class Antihyperglycaemics
  • Mechanism of Action Glucagon like peptide 1 receptor agonists; Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 31 Jul 2018 Sanofi announces intention to submit regulatory application for Obesity in 2022
  • 22 Jun 2018 Pharmacodynamics and pharmacokinetics data from a phase I trial in Type 2 diabetes mellitus presented at the 78th Annual Scientific Sessions of the American Diabetes Association (ADA-2018)
  • 19 Feb 2018 Sanofi plans the phase II Restore trial for Non-alcoholic steatohepatitis in USA (SC,Injection) (NCT03437720)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top